Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema
Purpose. Diabetic macular edema (DME) is a vision-threatening condition that develops in diabetic patients. The first-line therapy for DME is intravitreal injections of antivascular endothelial growth factor (anti-VEGF) agents; however, the high frequency of repeat injections, invasiveness of the pr...
Saved in:
| Main Authors: | Yoko Takatsuna, Ryoichi Ishibashi, Tomoaki Tatsumi, Masaya Koshizaka, Takayuki Baba, Shuichi Yamamoto, Koutaro Yokote |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Ophthalmological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2020/8867079 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparisons of One to Three Monthly Injections of Aflibercept for Diabetic Macular Edema by Practical Protocol
by: Yuko Hayashi, et al.
Published: (2021-01-01) -
Sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic macular edema and the need for intravitreal injection
by: Yoo-Ri Chung, et al.
Published: (2025-07-01) -
Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
by: A. M. Mkrtumyan, et al.
Published: (2021-09-01) -
Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents
by: E. R. Radkevich, et al.
Published: (2025-05-01) -
Sodium-glucose cotransporter 2 inhibitor for the treatment of diabetic nephropathy
by: Kong Ling-li, et al.
Published: (2021-01-01)